1810037I17Rik Activators are a specialized group of chemical compounds that act on various signaling pathways to enhance the activity of 1810037I17Rik. Forskolin, by raising cAMP levels, indirectly augments the activity of 1810037I17Rik through the activation of PKA, which may phosphorylate and thereby activate 1810037I17Rik itself or associated regulatory proteins. In parallel, IBMX increases cAMP by inhibiting its degradation, which also indirectly promotes 1810037I17Rik activity. Additionally, Epigallocatechin gallate and Genistein serve as kinase inhibitors, potentially relieving 1810037I17Rik from inhibitory phosphorylation or modulating kinase-regulated signaling pathways that interact with 1810037I17Rik. PMA, through activation of PKC, and U0126, by inhibiting MEK1/2, offer additional pathways to enhance 1810037I17Rik activity, either through direct phosphorylation or by altering the phosphorylation state of proteins within the MAPK pathway. This particular gene is relevant to the function and regulation of certain cellular processes in mice.
During this screening, the 1810037I17Rik gene promoter is typically linked to a reporter gene, such as luciferase, to create a reporter assay system. This system is designed to emit a measurable light signal when the promoter is activated. Compounds that trigger a significant increase in luminescence are indicative of interaction with the promoter, resulting in gene activation. These compounds are then considered candidates for 1810037I17Rik Activators and are subjected to further validation to confirm their activity. Quantitative PCR (qPCR) is used to measure the mRNA levels of the 1810037I17Rik gene after the application of the compounds, providing a direct assessment of gene expression. This technique quantifies the expression levels to confirm that the mRNA is being produced at elevated levels upon compound interaction. Western blot analysis is subsequently conducted to determine if the increase in mRNA is matched by an increase in the production of the corresponding protein.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective phosphodiesterase inhibitor, leading to increased cAMP by preventing its breakdown. This accumulation can indirectly enhance 1810037I17Rik activity if 1810037I17Rik function is modulated by cAMP-dependent signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
This polyphenol inhibits several protein kinases, potentially reducing negative regulatory phosphorylation events, which could lead to enhanced activity of 1810037I17Rik if it is regulated by such kinases. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may enhance the activity of 1810037I17Rik by phosphorylating it directly or phosphorylating associated regulatory proteins that influence 1810037I17Rik's functional state. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that could lead to increased activity of 1810037I17Rik by altering signaling pathways that negatively regulate 1810037I17Rik through PI3K-dependent pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
This lipid signaling molecule could enhance 1810037I17Rik activity by activating sphingosine-1-phosphate receptors that may be part of signaling cascades interacting with 1810037I17Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin raises intracellular calcium levels by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). Increased calcium signaling might enhance 1810037I17Rik activity if calcium-dependent signaling pathways modulate it. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium concentration, which could indirectly enhance the activity of 1810037I17Rik through activation of calcium-dependent signaling pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
As a broad-spectrum kinase inhibitor, staurosporine might non-selectively enhance 1810037I17Rik activity by inhibiting kinases that negatively regulate 1810037I17Rik or its associated signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may enhance 1810037I17Rik activity by reducing competitive phosphorylation events or by modulating signaling pathways that intersect with tyrosine kinase-regulated processes involving 1810037I17Rik. | ||||||